Novavax has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus, under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville.
ImmunoVaccine Technologies (IVT) has signed an agreement with UK-based Scancell. The research agreement will explore the potential of using IVT’s DepoVax delivery system for Scancell’s novel ImmunoBody DNA
Generex has reported the publication of pre-clinical studies conducted to identify vaccine peptides, for the potentially pandemic H5N1 avian influenza virus. The report is the result of a
Anesiva and Arcion have signed a definitive merger agreement. The merger is likely to result in a public company with a portfolio of late-stage targeted pain therapeutics. The
EpiCept has filed a New Drug Submission (NDS) with Health Canada for Ceplene (histamine dihydrochloride), for the treatment of acute myeloid leukemia (AML) patients in first complete remission.
Amarillo Biosciences has completed full enrollment in a phase 2 clinical study of its oral interferon product at the University of Western Australia, located in Perth. Reportedly, a
Law firm, Shalov Stone Bonner & Roccohas has filed a lawsuit seeking a class action status (on behalf of purchasers of the securities of Caraco) in US District
In light of the foregoing, the directors of the Corporation have resigned. The implications for creditors and other stakeholders of the Corporation are not known at this time
Lexicon has initiated a phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis. The company has also completed a drug-drug interaction (DDI) study of LX2931 with
Allos Therapeutics has reported a net loss of $16.8 million, or $0.19 per share for second quarter of 2009, compared to a net loss of $11.8 million, or
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.